v3.26.1
License and Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
ProductCandidate
Aug. 31, 2025
USD ($)
Mar. 31, 2025
USD ($)
Nov. 30, 2021
USD ($)
Jun. 30, 2026
USD ($)
ProductCandidate
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Country
ProductCandidate
Jun. 30, 2025
USD ($)
Mar. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone payment upon commencement of clinical trials in humans             $ 444,000,000        
Milestone payment upon submission of regulatory approval filings             86,500,000        
Milestone payment upon achievement of specified sales targets for licensed products             1,530,000,000        
Deferred revenue, current and non-current $ 25,286,000   $ 39,885,000   $ 25,286,000 $ 37,781,000 25,286,000 $ 37,781,000 $ 28,695,000 $ 29,395,000 $ 115,000
Aggregate transaction price of license agreements             $ 27,400,000        
Aggregate transaction price of license agreements, expected satisfaction period             5 years        
Revenue recognized upon achievement of development milestones         100,000,000 0 $ 100,000,000 0      
Accounts receivable 107,189,000   19,400,000   107,189,000 21,783,000 107,189,000 21,783,000 $ 10,458,000 28,691,000 $ 20,947,000
Accounts receivable, Current 106,754,000       106,754,000   106,754,000     26,379,000  
Accounts receivable, Non current 435,000       435,000   435,000     2,312,000  
Milestone payment receivable 100,000,000       100,000,000   100,000,000        
Abb Vie Collaboration And License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue recognized upon achievement of development milestones         100,000,000   100,000,000        
Up-front fee paid       $ 370,000,000              
Milestone fee payments upon achievement of various development and commercialization       1,380,000,000              
Transaction price of license 470,000,000     470,000,000 470,000,000   470,000,000        
Transaction price of licence increase in amount upon achievement of First DR Milestone 100,000,000       100,000,000   100,000,000        
Up-front payment received       370              
Change in transaction price           $ 0   $ 0      
Milestone due   $ 200,000,000                  
Milestone payment due upon achievement of First DR Milestone 100,000,000                    
Milestone payment upon first patient dosed in the Phase IIb/III trial   100,000,000                  
Milestone payment earned upon achievement of First DR Milestone 100,000,000                    
Milestone payment upon first patient dosed in the subsequent Phase III trial   $ 100,000,000                  
Abb Vie Collaboration And License Agreement | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherAssetsCurrent                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Due from related parties, current 10,500,000       10,500,000   10,500,000     10,900,000  
Nippon Shinyaku Collaboration and License Agreement [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Accounts receivable 2,500,000       2,500,000   2,500,000     4,100,000  
Deferred revenue 25,300,000       25,300,000   25,300,000     29,400,000  
Deferred revenue, Current 9,900,000       9,900,000   9,900,000     10,500,000  
Deferred revenue, Noncurrent 15,400,000       15,400,000   15,400,000     18,900,000  
Up-front fee paid     110,000,000                
Transaction price of license 110,000,000       110,000,000   110,000,000        
Estimated variable consideration 6,200,000       6,200,000   6,200,000        
Novartis License Agreement [Member] | Novartis [ Member ]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Accounts receivable 4,400,000       4,400,000   4,400,000     $ 24,100,000  
Sales Based Milestones | Abb Vie Collaboration And License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee payments upon achievement of various development and commercialization       820,000,000              
Transaction price of license 820,000,000       820,000,000   820,000,000        
Sales Based Milestones | Nippon Shinyaku Collaboration and License Agreement [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee received upon achievement of specified development and sales based milestones     660,000,000                
Transaction price of license 660,000,000       660,000,000   660,000,000        
Development Milestone | Abb Vie Collaboration And License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee payments upon achievement of various development and commercialization       $ 562,500,000              
Transaction price of license 462,500,000       462,500,000   462,500,000        
Development Milestone | Nippon Shinyaku Collaboration and License Agreement [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee received upon achievement of specified development and sales based milestones     40,000,000                
Transaction price of license $ 40,000,000       $ 40,000,000   40,000,000        
Maximum [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Aggregate milestone payment for all the targets             $ 2,060,000,000.00        
Maximum [Member] | Nippon Shinyaku Collaboration and License Agreement [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Milestone fee received upon achievement of specified development and sales based milestones     $ 700,000,000                
N A V Technology Platform [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of commercial product candidates | ProductCandidate 2       2   2        
HCR [Member] | Novartis License Agreement [Member] | Novartis [ Member ]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Accounts receivable, current $ 3,300,000       $ 3,300,000   $ 3,300,000        
Zolgensma Royalties [Member]                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of countries where licensed patents remain active | Country             20